4D Molecular Therapeutics Started Phase 3 Diabetes Trial
The company has enrolled the first patients for a study evaluating the efficacy of its gene therapy 4D-150.
Updated on Sept. 28, 2026 in Diabetes
Live Poll
Do you trust that new medical therapies can successfully replace frequent injection schedules for chronic diseases?
4D Molecular Therapeutics has initiated the 4SIGHT Phase 3 clinical trial to evaluate 4D-150 as a treatment for diabetic macular edema. The global study is designed to assess the therapy in 514 patients who suffer from vision-threatening complications related to diabetes.
Why it matters
Many patients with diabetic macular edema struggle with treatment adherence due to the high frequency of required anti-VEGF injections. 4D-150 aims to reduce this significant treatment burden by providing a sustained alternative for long-term disease control.
The 4SIGHT trial is a multicenter, randomized, double-masked study that compares the single-injection 4D-150 treatment against a 2 mg aflibercept comparator. The study's primary endpoint assessment is scheduled for week 52.
The players
4D Molecular Therapeutics
Headquartered in Emeryville, California, this biotechnology company focuses on the development of gene therapy products.
Food and Drug Administration
This federal agency is responsible for protecting public health by ensuring the safety and efficacy of medical products.
The details
Participants in the 4SIGHT trial receive five aflibercept loading doses during an initial run-in period before transitioning to the experimental gene therapy. The drug has already received Regenerative Medicine Advanced Therapy designation from the FDA, and the company intends to use trial data to support a future Biologics License Application.
Timeline
March 12, 2026: Data cutoff date for the SPECTRA clinical trial.
September 28, 2026: 4D Molecular Therapeutics announced the initiation of the 4SIGHT trial.
Week 52: Primary endpoint assessment scheduled for the 4SIGHT trial.
The Big Picture
This development follows the FDA Regenerative Medicine Advanced Therapy designation program, which serves to expedite the development of therapies for serious conditions with high unmet needs. This trial marks a pivotal step in positioning 4D-150 as a continuous backbone therapy for retinal diseases.
Patients currently dealing with the requirement for frequent eye injections may eventually benefit from a reduced treatment burden if 4D-150 is successfully approved. This therapy represents a shift toward more sustained, long-term disease management for those with diabetic eye conditions.
The takeaway
The transition toward single-injection gene therapies aims to solve long-standing adherence issues in chronic ocular care. Patients should consult with their ophthalmologists about how emerging long-term therapies may fit into their future treatment plans.
Further reading
For more information on current treatment trends, visit the Diabetes section.
Live Poll
Do you trust that new medical therapies can successfully replace frequent injection schedules for chronic diseases?
